Arnvis Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 355.09%
- Profit Growth 500.19%
- Ebitda -126.40%
- Net Worth 52.08%
- Total Assets 310.10%
About Arnvis Pharma
Arnvis Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 November 2018 (Six years and two months 22 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Patnala Vardhani, Patanala Shastry, Chandrakala Mandarapu, and One other member serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24299UP2018PTC110252
-
Company No.
110252
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Nov 2018
-
Date of AGM
17 Jan 2022
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Arnvis Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Patanala Shastry
|
Managing Director | 13-Nov-2018 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Mandarapu Kumar
|
Director | 13-Nov-2018 | Current |
|
Patnala Vardhani
|
Director | 13-Nov-2018 | Current |
|
Chandrakala Mandarapu
|
Director | 13-Nov-2018 | Current |
Financial Performance of Arnvis Pharma.
Arnvis Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 355.09% increase. The company also saw a substantial improvement in profitability, with a 500.19% increase in profit. The company's net worth Soared by an impressive increase of 52.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arnvis Pharma?
Unlock access to Arnvis Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Paavni Builders Private LimitedPatnala Vardhani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arnvis Pharma?
Unlock and access historical data on people associated with Arnvis Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arnvis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arnvis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.